The Official Website of the Long-Term Investor
Results 1 - 10 of 109 : 1 2 3 4 5 6 7 8 9 Next
Has Arena Pharmaceuticals Become the Perfect Stock?
Finding companies that have all the right stuff can produce winners.
Don't Believe This Company's Warning
VIVUS' news is great news.
This Biotech's Obese To-Do List Is Done
Arena resubmits lorcaserin for FDA approval.
Working Through the Obese To-Do List in 2011
Arena ends the year on an upswing.
Qnexa data can't be ignored.
Highlighting the day's health-care stories critical to investors.
Aeterna Zentaris Surprises Again
A quarterly profit shocks analysts and me alike.
These stocks have been looking up over the past month.
Closer to Approval, Now Can MELA Find Customers?
The restrictions might be too much.
Obesity-Drug Makers Stop Getting Bullied
Don't count on approvals; they're still a long shot.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK